论文部分内容阅读
目的利用去除Ｅ７的转化活性而保留其抗原性的Ｅ７Ｃ亚基因研制防治ＨＰＶ１６相关疾病的疫苗，并进一步探索利用Ｂ７－１研制更佳活化细胞免疫的加强疫苗。方法用ＰＣＲ方法扩增获得Ｅ７Ｃ后，插入真核表达质粒获得ｐＬＮＣＥ７Ｃ，体外真核细胞中证实其具有表达能力后，在Ｃ５７ＢＬ／６小鼠后腿肌肉内直接进行裸ＤＮＡ接种免疫，或与ｐＬＮＣｍＢ７－１联合免疫接种，用５１Ｃｒ释放法体外分析经免疫鼠的细胞毒性Ｔ淋巴细胞活性。结果经免疫小鼠获得较好的Ｅ７特异性ＣＴＬ活性；若Ｅ７Ｃ与小鼠Ｂ７－１的表达质粒联合接种，则活性明显得到加强。结论Ｅ７Ｃ可以用于ＨＰＶ１６ＤＮＡ疫苗研制，Ｂ７－１具有推广应用价值
Objective To develop a vaccine against HPV16-related diseases using the E7C subunit, which removes the antigenicity of E7 but also to retain its antigenicity, and to further explore the use of B7-1 in the development of enhanced vaccines for better activated cell immunity. Methods E7C was amplified by PCR and inserted into eukaryotic expression plasmid to obtain pLNCE7C. The eukaryotic cells were confirmed to express pLNCE7C, and then directly inoculated with naked DNA in the hind leg muscle of C57BL / 6 mice or immunized with pLNCmB7 -1, and cytotoxic T lymphocyte activity of immunized mice was analyzed in vitro by 51Cr release assay. Results The E7-specific CTL activity of the immunized mice was better than that of the control. E7C and B7-1 mouse plasmids were significantly increased. Conclusion E7C can be used for HPV16 DNA vaccine development, B7-1 has the promotion and application value